Category Archives: Prevention, Engagement and Care Cascade

Efavirenz versus protease inhibitors in patients with HIV: A systematic review and meta-analysis

2021

Efavirenz- and protease inhibitor (PI)-based regimens remain viable options across the globe. We conducted a meta-analysis to compare the effectiveness of efavirenz-based regimens relative to PI-based regimens. EMBASE, PubMed, Cochrane,...

Low inducibility of latent human immunodeficiency virus type 1 proviruses as a major barrier to cure

2021

The latent reservoir for human immunodeficiency virus type 1 (HIV-1) in resting CD4+ T cells is a major barrier to cure. The dimensions of the reservoir problem can be defined...

Evidence and gaps in the literature on HIV/STI prevention interventions targeting migrants in receiving countries: A scoping review

2021

BACKGROUND: Evidence suggests that migration increases vulnerability to human immunodeficiency virus (HIV) and other sexually transmitted infections (STI). However, there is limited knowledge about what has been done or needs...

Recommendations for increasing physician provision of pre-exposure prophylaxis: Implications for medical student training

2021

There is growing evidence that pre-exposure prophylaxis (PrEP) prevents HIV acquisition. However, in the United States, approximately only 4% of people who could benefit from PrEP are currently receiving it,...

1,2,3-Triazole hybrids with anti-HIV-1 activity

2021

The human immunodeficiency virus type 1 (HIV-1) is the major etiological agent responsible for the acquired immunodeficiency syndrome (AIDS), which is a serious infectious disease and remains one of the...

What’s new in bone disease and fractures in HIV?

2021

PURPOSE OF REVIEW: People living with HIV (PWH) are at greater risk of low bone mineral density (BMD) and fractures compared to the general population. This narrative review summarises recent...

Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV

2021

PURPOSE OF REVIEW: To highlight mechanisms of elevated risk of atherosclerotic cardiovascular disease (ASCVD) among people living with HIV (PLWH), discuss therapeutic strategies, and opportunities for primary prevention. RECENT FINDINGS:...

Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficency virus infection

2021

PURPOSE OF REVIEW: Despite antiretroviral therapy (ART)-mediated viral suppression, people with human immunodeficiency virus (HIV) (PWH) have increased morbidity and mortality. Immune activation and inflammation persist on ART and predict...

Current co-morbidities burden in patients living with HIV in low- and middle-income countries

2021

PURPOSE OF REVIEW: The present review aims to decipher common co-morbidities faced by people living with HIV in low- to middle-income countries, and in particular the sub-Saharan region, which hosts...

Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV

2021

PURPOSE OF REVIEW: Obesity is increasing in people with HIV (PWH). This review aims to summarise the recent evidence investigating the associations between the use of integrase inhibitors and tenofovir...

Recent data on adipose tissue, insulin resistance, diabetes and dyslipidaemia in antiretroviral therapy controlled HIV-infected persons

2021

PURPOSE OF REVIEW: Increased total body fat with truncal redistribution is common in antiretroviral therapy (ART)-controlled persons living with HIV(PLWH), leading to insulin resistance, prediabetes/diabetes and dyslipidaemia. We address these...

A review of chronic comorbidities in adults living with HIV: State of the science

2021

People living with HIV are living longer, high-quality lives; however, as they age, this population is at increased risk for developing chronic comorbidities, including cardiovascular disease, certain types of cancer...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!